PURPOSE: The P2X7 receptor, an adenosine triphosphate (ATP)-gated purinoreceptor, has emerged as one of the key players in neuroinflammatory processes. Therefore, developing a positron emission tomography (PET) tracer for imaging of P2X7 receptors in vivo presents a promising approach to diagnose, monitor, and study neuroinflammation in a variety of brain disorders. To fulfill the goal of developing a P2X7 PET ligand as a biomarker of neuroinflammation, [18F]JNJ-64413739 has been recently disclosed. PROCEDURES: We evaluated [18F]JNJ-64413739 in a rat model of neuroinflammation induced by an intracerebral injection of lipopolysaccharide (LPS). In vivo brain uptake was determined by PET imaging. Upregulation of neuroinflammatory biomarkers was determined by quantitative polymerase chain reaction (qPCR). Distribution of the tracer in the brain was determined by ex vivo autoradiography (ARG). The specificity of [18F]JNJ-64413739 was confirmed by performing blocking experiments with the P2X7 antagonist JNJ-54175446. RESULTS: Brain regions of rats injected with LPS had a significantly increased uptake (34 % ± 3 % s.e.m., p = 0.036, t test, standardized uptake value measured over the entire scanning period) of [18F]JNJ-64413739 relative to the corresponding brain regions of control animals injected with phosphate-buffered saline (PBS). The uptake in the contralateral regions and cerebellum was not significantly different between the groups of animals. The increase in uptake of [18F]JNJ-64413739 at the LPS-injected site observed by PET imaging was concordant with ex vivo ARG, upregulation of neuroinflammatory biomarkers, and elevated P2X7 expression levels. CONCLUSIONS: While further work is needed to study [18F]JNJ-64413739 in other types of neuroinflammation, the current results favorably characterize [18F]JNJ-64413739 as a potential PET tracer of central neuroinflammation.
PURPOSE: The P2X7 receptor, an adenosine triphosphate (ATP)-gated purinoreceptor, has emerged as one of the key players in neuroinflammatory processes. Therefore, developing a positron emission tomography (PET) tracer for imaging of P2X7 receptors in vivo presents a promising approach to diagnose, monitor, and study neuroinflammation in a variety of brain disorders. To fulfill the goal of developing a P2X7 PET ligand as a biomarker of neuroinflammation, [18F]JNJ-64413739 has been recently disclosed. PROCEDURES: We evaluated [18F]JNJ-64413739 in a rat model of neuroinflammation induced by an intracerebral injection of lipopolysaccharide (LPS). In vivo brain uptake was determined by PET imaging. Upregulation of neuroinflammatory biomarkers was determined by quantitative polymerase chain reaction (qPCR). Distribution of the tracer in the brain was determined by ex vivo autoradiography (ARG). The specificity of [18F]JNJ-64413739 was confirmed by performing blocking experiments with the P2X7 antagonist JNJ-54175446. RESULTS: Brain regions of rats injected with LPS had a significantly increased uptake (34 % ± 3 % s.e.m., p = 0.036, t test, standardized uptake value measured over the entire scanning period) of [18F]JNJ-64413739 relative to the corresponding brain regions of control animals injected with phosphate-buffered saline (PBS). The uptake in the contralateral regions and cerebellum was not significantly different between the groups of animals. The increase in uptake of [18F]JNJ-64413739 at the LPS-injected site observed by PET imaging was concordant with ex vivo ARG, upregulation of neuroinflammatory biomarkers, and elevated P2X7 expression levels. CONCLUSIONS: While further work is needed to study [18F]JNJ-64413739 in other types of neuroinflammation, the current results favorably characterize [18F]JNJ-64413739 as a potential PET tracer of central neuroinflammation.
Authors: Brian Lord; Leah Aluisio; James R Shoblock; Robert A Neff; Elena I Varlinskaya; Marc Ceusters; Timothy W Lovenberg; Nicholas Carruthers; Pascal Bonaventure; Michael A Letavic; Terrence Deak; Wilhelmus Drinkenburg; Anindya Bhattacharya Journal: J Pharmacol Exp Ther Date: 2014-09-30 Impact factor: 4.030
Authors: Sina Hafizi; Tania Da Silva; Cory Gerritsen; Michael Kiang; R Michael Bagby; Ivana Prce; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi Journal: Neuropsychopharmacology Date: 2017-06-12 Impact factor: 7.853
Authors: Thalia F van der Doef; Lot D de Witte; Arjen L Sutterland; Ellen Jobse; Maqsood Yaqub; Ronald Boellaard; Lieuwe de Haan; Jonas Eriksson; Adriaan A Lammertsma; René S Kahn; Bart N M van Berckel Journal: NPJ Schizophr Date: 2016-08-31
Authors: M A Di Biase; A Zalesky; G O'keefe; L Laskaris; B T Baune; C S Weickert; J Olver; P D McGorry; G P Amminger; B Nelson; A M Scott; I Hickie; R Banati; F Turkheimer; M Yaqub; I P Everall; C Pantelis; V Cropley Journal: Transl Psychiatry Date: 2017-08-29 Impact factor: 6.222
Authors: Jeffrey H Meyer; Simon Cervenka; Min-Jeong Kim; William C Kreisl; Ioline D Henter; Robert B Innis Journal: Lancet Psychiatry Date: 2020-10-21 Impact factor: 27.083
Authors: Donatienne Van Weehaeghe; Michel Koole; Mark E Schmidt; Stephanie Deman; Andreas H Jacobs; Erika Souche; Kim Serdons; Stefan Sunaert; Guy Bormans; Wim Vandenberghe; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-26 Impact factor: 9.236
Authors: Melissa Crabbé; Anke Van der Perren; Ilse Bollaerts; Savannah Kounelis; Veerle Baekelandt; Guy Bormans; Cindy Casteels; Lieve Moons; Koen Van Laere Journal: Front Neurosci Date: 2019-07-31 Impact factor: 4.677
Authors: Lingling Zhang; Kuan Hu; Tuo Shao; Lu Hou; Shaojuan Zhang; Weijian Ye; Lee Josephson; Jeffrey H Meyer; Ming-Rong Zhang; Neil Vasdev; Jinghao Wang; Hao Xu; Lu Wang; Steven H Liang Journal: Acta Pharm Sin B Date: 2020-08-25 Impact factor: 11.413
Authors: Wissam Beaino; Bieneke Janssen; Esther Kooijman; Ricardo Vos; Robert C Schuit; James O'Brien-Brown; Michael Kassiou; Bert van Het Hof; Danielle J Vugts; Helga E de Vries; Albert D Windhorst Journal: J Neuroinflammation Date: 2020-10-14 Impact factor: 8.322